Internal Medicine Section DOI : 10.7860/JCDR/2020/42745.13488
Year : 2020 | Month : Feb | Volume : 14 | Issue : 02 Page : OC15 - OC17

Assessment of Pentosidine as a Marker for Advanced Glycation End Products in Type 2 Diabetes Mellitus Patients

Sarath Kumar Jaganathan Jaishankar1, Amrutha Murali2, Amrin Marzooka3

1 Medical Student, Department of Biochemistry, Kilpauk Medical College, Chennai, Tamil Nadu, India.
2 Medical Student, Department of Biochemistry, Kilpauk Medical College, Chennai, Tamil Nadu, India.
3 Medical Student, Department of Biochemistry, Kilpauk Medical College, Chennai, Tamil Nadu, India.


NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR: Mr. Sarath Kumar Jaganathan Jaishankar, Jains Westminster, Saligramam, Chennai, Tamil Nadu, India.
E-mail: drjjsarathkumar@gmail.com
Abstract

Introduction

With Diabetes Mellitus (DM) becoming a global burden, quantifying the number of people affected, both now and in the future, is vital so that the preventive component of diabetes and its complications can be emphasised. Many studies suggest that DM associated with persistent or uncontrolled hyperglycaemia leads to the production of Advanced Glycation End Products (AGEs) and Advanced Oxidation Protein Products (AOPPs) resulting in various micro and macrovascular complications. Pentosidine, an AGE, is a glycated protein product formed as a result of non-enzymatic glycation, mainly Maillard reaction between plasma glucose and plasma proteins.

Aim

To determine the efficacy of pentosidine as a marker for AGEs in Type 2 DM patients.

Materials and Methods

A case-control study was conducted in a tertiary care institution with approval of the institutional ethical committee August to September 2014. Forty four individuals who have been diagnosed with type 2 DM for more than five years were taken as cases and 44 healthy individuals who were age and gender matched were included as controls. The medications taken by cases were: Metformin (n=44); Glimepiride (n=26); Glibenclamide (n=7); Glipizide (n=4); and Atorvastatin (n=44). All the participants underwent routine and special (AGEs-pentosidine-ELISA) investigations. Data were analysed using the SPSS version 16 software.

Results

In this study, the mean level of pentosidine (AGE) among cases was 3.073 ng/dL, and among controls was 2.682 ng/dL. Although the levels of pentosidine (AGE) was found to be higher in cases than controls, this difference among the groups was not found to be statistically significant.

Conclusion

Levels of AGEs (pentosidine) in cases were higher than the controls, but not statistically significant. Although AGEs have been considered to play a role in the development of many micro and macro angiopathic complications both independently and synergistically in patients with DM, it must be conducted on a larger scale to extrapolate the results in order to assess the effectiveness of AGEs in supplementing routine investigations.

Introduction

Diabetes is a grave, chronic condition [1]. In 2013, the global estimate of diabetes was found to be 382 million, and this number is expected to rise to 592 million by 2035 [2]. The number of people with DM, especially type 2 diabetes, is increasing at an alarming rate, and so are the complications associated with it [3,4], due to the population growth, ageing, urbanisation, increasing prevalence of obesity, and physical inactivity. Thus, quantifying the prevalence of diabetes, is essential so that the prevention aspect of it and its complications can be stressed upon [5,6].

Persistent hyperglycaemia in DM is associated with accelerated non-enzymatic protein-glucose condensation reactions, oxidative stress and carbonyl stress. These mechanisms result in the formation of AGEs such as Pentosidine, Carboxymethyl lysine, pyralline, GOLD-Glyoxal-lysine dimer, MOLD- Methyl glyoxal lysine dimer, Carboxy ethyl lysine, etc., and AOPP which inflict damages to biologically important compounds [5,7]. AGEs are formed when plasma glucose binds to serum albumin (plasma protein) and undergoes the Maillard reaction which is a non-enzymatic. AGEs and AOPPs have a role in the pathogenesis of retinopathy, atherosclerosis, neuropathy, nephropathy, diabetic embryopathy, impaired wound healing, etc. AGEs are related to the development and progression of heart failure in non-diabetic patients as well [8-10]. These complications, when looked at a cellular level occur as a result of interaction between AGEs, and certain specific and non-specific receptor systems. One of the main interactions which have been described by various studies is Receptor for Advanced Glycation End-Products (AGE-RAGE) interaction. This results in the activation of intracellular mechanisms responsible for the toxic effects [11].

As AGEs are irreversibly formed compounds [12], which are present even if the plasma glucose levels are normalised after persistent glycaemia, it is crucial to recognise methodologies to prevent the dreaded complications even before they show initial signs. Such methodologies, when found to prove the merits of this hypothesis, they should supplement routine investigations. Among the many AGEs being studied, pentosidine has been well characterised as a compound associated with diabetic complications. Hence, this study was conducted to the efficacy of pentosidine as a marker for AGE products in Type 2 DM patients.

Materials and Methods

A case-control study was conducted in a tertiary care institution with the approval (2014/1977/9) of the institutional ethical committee during the period of August to September 2014 among 88 individuals after obtaining informed consent. The number of participants selected was calculated with an error margin of 3% and a confidence interval of 95% of the total sample size of 96 based on the ELISA test requirements (total 96 strip wells). A total of 44 individuals of both genders who have been diagnosed with type 2 DM for more than 5 years, regardless of age with no apparent complications due to diabetes, were taken as cases, and 44 healthy individuals who were non-smokers, non-alcoholic, with no DM and hypertension, age and gender matched were included as controls in the study. Patients with type 1 DM, hypertension, coronary artery disease, and subjects taking anti-oxidants were excluded from the study. The medications taken by cases were: Metformin (n=44); Glimepiride (n=26); Glibenclamide (n=7); Glipizide (n=4); and Atorvastatin (n=44).

The samples were collected from the Department of Diabetology and analysed in the Department of Biochemistry. From all the participants, 5 mL fasting venous blood sample was collected, and serum was separated by centrifugation at 3000 rpm for 10 minutes, aliquoted into Eppendorfs, and stored at -20°C for analysis. All the participants underwent routine investigations like fasting blood sugar using GOD/POD method, fasting lipid profile which included total cholesterol using CHOD-PAP method, triglyceride using GPO-PAP method, HDL cholesterol using direct Immuno-turbidimetry method, LDL cholesterol using direct Immunoturbidimetry method [13-16] and special investigation- AGEs-pentosidine-ELISA (bioassay technology laboratory- Cat. No E0004 Hu).

Statistical Analysis

Data was analysed using the SPSS version 16 software. Descriptive statistics were reported as mean (SD) for continuous variables and frequency (percentage) for categorical variables. Spearman’s rank correlation was used for univariate analysis. The groups were compared using analysis of Variance and t-test. A p-value <0.05 was considered as statistically significant.

Results

The study population consisted of 88 individuals- 44 cases with type 2 DM with no associated medical complications, for more than five years and 44 normal healthy controls. The study groups were matched for age (53±7 years), sex and risk factors. Comparison of biochemical parameters between the study groups are listed in [Table/Fig-1,2].

Comparison of fasting blood glucose and lipid profile between the study groups.

VariablesGroupNoMeanStd. DevT-scorep-value
Blood glucose (mg/dL)Case44183.25870.4687.618<0.001 S
Control4495.63529.237
Total cholesterol (mg/dL)Case44205.89051.7870.6360.526 NS
Control44213.62861.854
TGL (mg/dL)Case44180.51956.2640.3680.714 NS
Control44174.46293.953
HDL (mg/dL)Case4463.14312.3911.8030.075 NS
Control4468.66516.103
LDL (mg/dL)Case44108.76033.7991.7940.076 NS
Control4495.48435.618
VLDL (mg/dL)Case4436.10611.2530.3680.714 NS
Control4434.10618.791

p-value <0.05: significant; S: Significant; NS: Not significant


Independent samples t-test of ‘Case’ and ‘Control’ on AGE (pentosidine).

VariablesGroupNoMeanStd. DevT-scorep-value
AGEs (ng/dL) (Pentosidine)Case443.0734.2140.5730.568 NS
Control442.6821.660

p-value <0.05: significant; S: Significant; NS: Not significant


In the cases, blood sugar levels were found to be significantly higher than the controls (p< 0.001). Lipid levels of cases were higher than controls except the total cholesterol as all the cases were under statin therapy.

[Table/Fig-2] indicates the mean pentosidine level (AGE) in cases of 3.073 ng/dL and controls with a mean value of 2.682 ng/dL. Although the levels are higher in the cases relative to the controls, they were not statistically significant.

[Table/Fig-3] indicates that there is no significant correlation between glucose levels and pentosidine.

Correlation between glucose levels and AGE (pentosidine).

Overall correlation
GlucoseAGE
GlucosePearson correlation1-0.017
Sig. (2-tailed)0.876
N8888
AGE-PentosidinePearson correlation-0.0171
Sig. (2-tailed)0.876
N8888

Overall: r= -0.17, p=0.87


Discussion

This study was conducted to identify a marker for AGEs in type 2 DM patients, as many studies have suggested the role of AGEs in the development and progression of chronic diabetes complications. Among the many AGEs identified, pentosidine has been well-described to be a good predictor of various vascular complications associated with diabetes.

This case-control study consisted of 88 participants. Cases included 44 people who were diagnosed with Type 2 DM for more than five years, with no associated diabetic complications attending the diabetology out-patient department in a tertiary care teaching hospital in Chennai, India which caters to the patient population from various cities and towns nearby with varying socio-economic status, and controls included 44 healthy individuals, age and sex matched.

The main finding of this study was that the levels of pentosidine (AGE) were found to be higher in cases than controls, but this disparity between the groups was not found to be statistically significant (p=0.568). Other observations showed a significant difference in blood glucose levels between cases and controls (p≤0.001). Although the blood lipid levels except total cholesterol were higher in cases than controls, no statistically significant difference was found, as all patients (cases) were taking atorvastatin.

Although the levels of pentosidine were not significantly higher in cases than controls, the findings were in accordance with Sugiyama S et al., who found no difference in pentosidine levels between diabetic patients and healthy control subjects [17]. This study further suggests that plasma pentosidine levels are significantly influenced by renal function, and are independent of the duration or control of diabetes. Although there were no recorded renal complications in the patients included in the present study, renal function tests mainly creatinine could have been measured to confirm the findings.

Dolhofer-Bliesener R et al., also identified only a small increase in AGE levels in diabetic patients with normal renal function when compared to healthy subjects [18]. The theory of compromised renal function that plays a role in the reduction of pentosidine levels is further confirmed by a study conducted by Gohda T et al., [19].

While Yoshida N et al., found significantly higher pentosidine levels in diabetic patients than in controls, it was only in patients with diabetes having cardiovascular diseases than those without CVD [20]. This contributes to the fact that, while pentosidine is favourably linked to cardiac complications of diabetes, a cause and effect relationship can be established only when the complication is present and not before it evolves.

A study conducted by Kanazawa I et al., showed that six months of treatment with either metformin or pioglitazone lowered serum pentosidine levels in patients with type 2 DM [21]. Another similar study by Haddad M et al., also found that the plasma levels of pentosidine significantly decreased in patients receiving metformin compared to untreated patients with metabolic syndrome [22]. As the common drug taken by all the cases was metformin, it is likely that pentosidine levels were influenced by the medication, similar to the observations found in the above-mentioned studies.

In summary, although there was no statistically significant difference in pentosidine levels between cases and controls, it provides a clue that there were other factors causing an increase in pentosidine (AGE) levels that could be related to stress induced hyperglycaemia, exogenous dietary sources, life style factors etc. Thus, further larger long-term prospective studies giving priority to factors affecting the metabolism of pentosidine and other AGEs should be pursued to prove the cause and effect relationship between pentosidine and diabetic complications.

Limitation(s)

A study sample from different ethnic groups with a history of dietary patterns would have given us insight into the various factors that could affect the levels of AGE products. Renal function tests could have been performed among the study groups as pentosidine undergoes renal elimination. HbA1c measurement in the control group could have been done to confirm any pre-existing diabetic condition/glucose intolerance as continuous glucose monitoring rather than a single glucose test will give a dynamic value.

Conclusion(s)

In this study, the levels of AGE products (pentosidine) in cases were higher than controls but were not found to be statistically significant. While AGEs have been known to play a role in the development of many micro and macro angiopathic complications, both individually and synergistically, in patients with DM, it must be performed on a larger scale to extrapolate the results in order to determine the efficacy of AGEs in complementing routine investigations with emphasis given to factors affecting the metabolism of AGEs.

p-value <0.05: significant; S: Significant; NS: Not significantp-value <0.05: significant; S: Significant; NS: Not significantOverall: r= -0.17, p=0.87

References

[1]World Health Organisation (WHO). (2016). Global report on Diabetes. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/204874/WHO_NMH_NVI_16.3_eng.pdf;jsessionid=E4A09E7B2362142C71E456A811F0B6A8?sequenc)  [Google Scholar]

[2]Deshpande AD, Harris-Hayes M, Schootman M, Epidemiology of diabetes and diabetes-related complications Phys Ther 2008 88(11):1254-64.10.2522/ptj.2008002018801858  [Google Scholar]  [CrossRef]  [PubMed]

[3]ICMR Guidelines for management of type 2 Diabetes. (2018). Retrieved from https://medibulletin.com/wpcontent/uploads/2018/05/ICMR.diabetesGuidelines.2018.pdf  [Google Scholar]

[4]Alberti KG, Zimmet PZ, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation Diabet Med 1998 15(7):539-53.10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S  [Google Scholar]  [CrossRef]

[5]Kalousová M, Skrha J, Zima T, Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus Physiol Res 2002 51(6):597-604.10.1159/00006695612566668  [Google Scholar]  [CrossRef]  [PubMed]

[6]Peppa M, Vlassara H, Advanced glycation end products and diabetic complications: A general overview Horm Athens Greece 2005 4(1):28-37.10.14310/horm.2002.1114016574629  [Google Scholar]  [CrossRef]  [PubMed]

[7]Singh R, Barden A, Mori T, Beilin L, Advanced glycation end-products: A review Diabetologia 2001 44(2):129-46.10.1007/s00125005159111270668  [Google Scholar]  [CrossRef]  [PubMed]

[8]Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP, AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus I. The AGE concept Cardiovasc Res 1998 37(3):586-600.10.1016/S0008-6363(97)00233-2  [Google Scholar]  [CrossRef]

[9]Goldin A, Beckman JA, Schmidt AM, Creager MA, Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 2006 114(6):597-605.10.1161/CIRCULATIONAHA.106.62185416894049  [Google Scholar]  [CrossRef]  [PubMed]

[10]Glomb MA, Monnier VM, Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction J Biol Chem 1995 270(17):10017-26.10.1074/jbc.270.17.100177730303  [Google Scholar]  [CrossRef]  [PubMed]

[11]Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis J Clin Invest 1996 98(5):1088-94.10.1172/JCI1188898787669   [Google Scholar]  [CrossRef]  [PubMed]

[12]Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L, The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: A review Mol Med 2018 24(1):5910.1186/s10020-018-0060-330470170  [Google Scholar]  [CrossRef]  [PubMed]

[13]Ambade VN, Sharma YV, Somani BL, Methods for estimation of blood glucose: A comparative evaluation Med J Armed Forces India 1998 54(2):131-33.10.1016/S0377-1237(17)30502-6  [Google Scholar]  [CrossRef]

[14]Sullivan DR, Kruijswijk Z, West CE, Kohlmeier M, Katan MB, Determination of serum triglycerides by an accurate enzymatic method not affected by free glycerol Clin Chem 1985 31(7):1227-28.10.1093/clinchem/31.7.12274006196  [Google Scholar]  [CrossRef]  [PubMed]

[15]Hafiane A, Genest J, High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk BBA Clin 2015 3:175-88.10.1016/j.bbacli.2015.01.00526674734  [Google Scholar]  [CrossRef]  [PubMed]

[16]Dong J, Guo H, Yang R, Li H, Wang S, Zhang J, Serum LDL-and HDL-cholesterol determined by ultracentrifugation and HPLC J Lipid Res 2011 52(2):383-88.10.1194/jlr.D00897921044945  [Google Scholar]  [CrossRef]  [PubMed]

[17]Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Plasma levels of pentosidine in diabetic patients: An advanced glycation end product J Am Soc Nephrol 1998 9(9):1681-88.  [Google Scholar]

[18]Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD, Immunological determination of advanced glycosylation end-products in human blood and urine Nephrol Dial Transplant 1995 10(5):657-64.  [Google Scholar]

[19]Gohda T, Tanimoto M, Moon JY, Gotoh H, Aoki T, Matsumoto M, Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function Diabetes Res Clin Pract 2008 81(2):196-201.10.1016/j.diabres.2008.04.01318550199  [Google Scholar]  [CrossRef]  [PubMed]

[20]Yoshida N, Okumura K, Aso Y, High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes Metabolism 2005 54(3):345-50.10.1016/j.metabol.2004.09.01415736112  [Google Scholar]  [CrossRef]  [PubMed]

[21]Kanazawa I, Yamamoto M, Yamaguchi T, Sugimoto T, Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus Exp Clin Endocrinol Diabetes 2011 119(06):362-65.10.1055/s-0030-126795321472665  [Google Scholar]  [CrossRef]  [PubMed]

[22]Haddad M, Knani I, Bouzidi H, Berriche O, Hammami M, Kerkeni M, Plasma levels of pentosidine, carboxymethyl-lysine, soluble receptor for advanced glycation end products and metabolic syndrome: The metformin effect Dis Markers 2016 2016:624826410.1155/2016/624826427829696  [Google Scholar]  [CrossRef]  [PubMed]